This study is testing a cell therapy called CART19 for children and young adults (ages 12-29) with Systemic Lupus Erythematosus (SLE), also known as lupus. Lupus is a disease where the body's immune system attacks its own tissues. CART19 cells are a type of immune cell that are specially modified to target and remove certain B cells, which are thought to play a key role in lupus. The study aims to see how safe CART19 is and how well it works in treating lupus, including those with kidney involvement (lupus nephritis) and those without. The study plans to enroll 24 participants. The main goal is to track any serious side effects of CART19 for up to 24 months after treatment.

Study design

This is a single-center, single-arm, open-label study, meaning all participants will receive the CART19 treatment and both you and the study team will know what treatment you are getting. It will involve 24 participants and has two phases: Phase 1 will focus on safety, and Phase 2 will look at both safety and how well the treatment works.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

You will be followed for up to 24 months after receiving the CART19 treatment to monitor for any side effects.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.